NHS Greenlights Controversial Endometriosis Tests

Two new non-invasive tests could shorten the long, frustrating road to an endometriosis diagnosis.

Quick Take

NICE has issued draft guidance backing EndoSure and Endotest for NHS primary care use during a three-year evidence-gathering period.
The tests are meant to help doctors spot endometriosis earlier without sending every patient straight to surgery.
Endotest uses saliva, while EndoSure uses abdominal sensor pads to pick up signals linked to the disease.
The promise is speed and comfort, but the NHS still wants real-world proof before making the tests routine.

What Changed in the NHS

The National Institute for Health and Care Excellence said two non-invasive technologies can be used in the National Health Service while more evidence is collected. The draft guidance covers EndoSure and Endotest, and it is aimed at primary care, where many women first seek help for symptoms that can take years to explain.

That matters because endometriosis often hides in plain sight. Patients can have severe pain, normal early exams, and mixed test results before anyone reaches a clear answer. The new guidance tries to give general practitioners a faster way to sort the likely cases from the unlikely ones.

How the Tests Work

Endotest looks at saliva for biological markers linked to endometriosis, while EndoSure uses sensor pads on the abdomen to measure electrical signals in the gut. Both are designed to be less invasive than laparoscopy, which has long been the main path to a firm diagnosis. In plain terms, the goal is to make the first step easier for patients and doctors.

That does not make them magic. NICE and reporting around the draft guidance make clear that the tests are not being treated as final, standalone answers. They are being introduced so the health service can learn how they perform in day-to-day practice, not just in ideal study settings.

Why This Could Matter So Much

Endometriosis diagnosis can drag on for years, and that delay can shape a patient’s whole life. The appeal of these tests is simple: faster sorting, earlier treatment, and less reliance on invasive surgery. Reporting on the guidance says the tests may help patients who have symptoms but normal clinical exams, or who cannot get useful ultrasound findings in primary care.

The bigger story is not just speed. It is access. A test that is easier to do in a family doctor’s office can change who gets seen, who gets referred, and who gets left waiting. If the NHS proves these tools work well outside specialist settings, they could shift endometriosis care from a long diagnostic hunt to a more direct path.

The Catch: Promise Needs Proof

The current approach is conditional, not final. NICE is allowing use while it collects evidence, and the guidance sets clear limits on where and how the tests should be used. That is the same sensible pattern the health system often uses with new diagnostics: open the door, but do not pretend the evidence is finished.

"Game changing."🥳

"Two new rapid tests, EndoSure and Endotest, can drastically reduce the wait time for a proper diagnosis of endometriosis—from an average nine-year wait to just days." This is GREAT🌟 #thereisgood❤️

Credit @goodnewsnetwork😊 https://t.co/5REzCSucb5 pic.twitter.com/5jNpRnzCVM

— Operation Kindness (@KindnessChamps) July 15, 2026

That caution matters. Tests that look strong in specialist studies can lose accuracy in busy real-world clinics, where patients are more mixed and the disease is harder to spot. The NHS is trying to avoid two mistakes at once: moving too slowly for women who have already waited too long, and moving too fast on tools that still need validation.

What Happens Next

The draft guidance now sits in consultation, with a final version expected after the review period. If NICE keeps the recommendation, the next phase will be the real test: whether these tools genuinely shorten diagnosis time, improve care, and reduce needless surgery. That is the point where hope turns into proof.

For patients, the practical change could be immediate once local services adopt the tests. For the health system, the change will be slower and more telling. If the evidence holds up, endometriosis may finally get the kind of first-line testing that many women have been denied for far too long.